跳至主要内容
临床试验/CTRI/2024/10/075920
CTRI/2024/10/075920尚未招募3 期

The effect of Mustadigana Kwatha orally and Palashakshara Yamaka Uttarbasti versus Dienogest in the management of Adenomyosis-An open label randomised controlled clinical trial

Dr Vimmi1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2024年11月15日最近更新:

试验速览

阶段
3 期
状态
尚未招募
发起方
入组人数
50
试验地点
1
主要终点
decrease in PBAC score,

研究概览

简要总结

Adenomyosis is the presence of ectopic endometrial glands within underlying myometrium. It is frequently diagnosed in young and infertile women. This disease is associated with pain or Abnormal uterine bleeding or both.  This trial is to evaluate and compare the combined effect of Mustadigana kwatha orally along with Palashkshara yamaka uttarbasti  versus Dienogest in managing adenomyosis and improving the quality of life .The trial will be performed in two groups consisting of 25 patients in each group. One group will be given Ayurvedic Management and the second group will receive Dienogest (2mg BD) for 3 consecutive months. The inclusion criteria includes -symptomatic patients have pure or dominant adenomyosis concurrent with uterine fibroids or endometriosis through USG , married women between age group of 30-45 years, those who are fit for Intrauterine Uttarbasti. Whereas exclusion criteria involves the patient having fribroids and endometriotic cyst of more than 5cm in size and endometrial thickness more than 11mm , Hb less than 8gm/dl , any congenital abnormalities, pregnant and lactating women,  uncontrolled hypertension or hyperthyroidism or hypothyroidism , uncontrolled Diabetes Mellitus. The primary expected outcome is decrease in PBAC score and VAS pain score , whereas secondary expected outcome is reduction of uterine volume / size of uterus and myometrial cysts (if any) evidenced by USG.

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
None

入排标准

年龄范围
30.00 Year(s) 至 45.00 Year(s)(—)
性别
Female

入选标准

  • symptomatic subjects having pure Adenomyosis or dominant adenomyosis concurrent with uterine fibroids or endometriosis through USG, Subjects presenting with any one complaint like menorrhagia (Heavy menstrual bleeding), Dysmenorrhea and chronic pelvic pain Married women with informed written consent, Subjects who are fit for Intrauterine Uttarbasti.

排除标准

  • Uterine fibroids more than 5cm size.
  • Pregnancy and lactation Uncontrolled hyperthyroidism and hypothyroidism, uncontrolled Hypertension, Diabetes Mellitus 2 Subjects with any congenital disorders Subjects with confirmed coagulopathy (based on signs and symptoms) Hb less than 8 gm/dl Active genital infections Adenomyosis along with endometriotic cyst more than 5cm Endometrial thickness more than 11mm Undiagnosed abnormal vaginal bleeding with in the last 3 months.

结局指标

主要结局

decrease in PBAC score,

时间窗: from 0th to 90th day

changes in VAS pain score per cycle

时间窗: from 0th to 90th day

次要结局

  • Reduction of uterine volume/ size of uterus and myometrial cyst (if any) evidenced by USG(From 0th to 90th day)

研究者

发起方
Dr Vimmi
申办方类型
Other [self]
责任方
Principal Investigator
主要研究者

Dr Vimmi

Shri Dhanwantry Ayurvedic College and Hospital

研究点 (1)

Loading locations...

相似试验